Carbios Posts €34.3 M FY25 Loss, Sets FY26 Plan to Scale Enzyme Recycling

Why It Matters

Carbios sits at the nexus of biotechnology and sustainability, and its enzymatic recycling platform could redefine how PET plastics are reclaimed. By moving from pilot to commercial scale, the company aims to cut greenhouse‑gas emissions associated with traditional mechanical recycling and virgin polymer production. Successful financing and licensing of the Longlaville plant would validate the economic viability of enzyme‑driven recycling, potentially unlocking further private and public investment in bio‑catalytic waste solutions. The FY26 strategy also signals a shift in the biotech business model: leveraging IP licensing to expand globally while limiting capital‑intensive plant ownership. If Carbios can secure Asian partners, it may accelerate adoption of its technology in markets where plastic waste volumes are rising fastest, thereby amplifying its environmental impact and creating a new revenue engine for the sector.

Key Takeaways

• FY25 net loss widened to €34.3 million ($37 million), driven by a non‑cash Carbiolice impairment
• Revenue grew to €5.74 million ($6.2 million) from grants and intra‑group services
• Operating expenses cut by €6.8 million ($7.3 million) after headcount reductions and cost refocusing
• CEO Vincent Kamel highlighted a new licensing agreement in Asia and progress on Longlaville financing
• FY26 priorities include restarting Longlaville plant, expanding Asian licensing, and scaling enzyme R&D

Pulse Analysis

Carbios’ FY25 results underscore the classic biotech trade‑off between heavy R&D spend and short‑term profitability. The widened loss is less a red flag than a symptom of a company transitioning from discovery to commercialization. By slashing operating costs and focusing on a licensing model, Carbios is hedging against the capital intensity of building full‑scale plants, a strategy that mirrors successful biotech firms that monetize platform technologies through royalty streams.

The Longlaville plant is the linchpin of Carbios’ commercial ambition. If financing closes, the facility could process up to 200,000 tonnes of PET annually, a scale that would make enzyme recycling cost‑competitive with conventional methods. However, the project’s success hinges on securing long‑term off‑take contracts and demonstrating that enzyme yields can be maintained at industrial volumes. A failure to do so could stall the broader adoption of bio‑catalytic recycling and dampen investor enthusiasm for similar ventures.

Finally, the Asian licensing push could be a game‑changer. China and India together generate over 30 million tonnes of PET waste each year, and regulatory pressure is mounting to adopt circular solutions. By offering a royalty‑based licensing framework, Carbios can rapidly embed its technology in local recycling ecosystems without bearing the full cost of plant construction. If early pilots deliver on cost and performance metrics, Carbios may set a template for biotech firms seeking to scale sustainability solutions globally.